NCT00841854

Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication

Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 199 (actual)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

At present, triple therapy are recommended by various guidelines for the treatment of Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment failure rates with one week first line clarithromycin based triple therapy necessitating salvage strategy to eradicate H. pylori in primary treatment failure. However, the exact duration of bismuth based second line treatment is not determined. Therefore, the investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple regimen as a second-line therapy.

Conditions

• Helicobacter Infection

Interventions

Type	Name	Description
DRUG	pantoprazole	pantoprazole 40mg bid
DRUG	bismuth	bismuth 300mg qid
DRUG	metronidazole	metronidazole 500mg tid
DRUG	tetracycline	tetracycline 500mg qid

Timeline

• Start date: 2008-06-01
• Primary completion: 2010-05-01
• Completion: 2010-11-01
• First posted: 2009-02-11
• Last updated: 2016-12-06

Locations

1 site across 1 country: South Korea